Jia-Yi Wu (Jiayi Wu)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Advanced Non Small Cell Lung Cancer

Binding Protein

Top Venues

Clinical case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Xia-Bo Shen, Jia-Yi Wu, Jia-Ying Li, Xi-Ying Shao, Xiao-Jia Wang
Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer. Clinical case reports 12 (4) (2024)
Jia-Yi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. Cancer 130 (S8) (2024)
Xia-Bo Shen, Jia-Yi Wu, Jia-Ying Li, Xi-Ying Shao, Xiao-Jia Wang
Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer. Clinical case reports 12 (4) (2024)
Jia-Yi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. Cancer 130 (S8) (2024)
Jia-Yi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. Cancer (2024)
Jia-Yi Wu, Wei Wang, Lu Gao, Xiying Shao, Xiaojia Wang
Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment. Cancer 130 (S8) (2024)